Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells

International Journal of Cancer

Volumn 105, Issue 6, 2003, Pages 820-824

  Wang, Yan Qing ^a,b   Ugai, Shin ichi ^a,c   Shimozato, Osamu ^a   Yu, Ling ^a   Kawamura, Kiyoko ^a   Yamamoto, Hiroshi ^d   Yamaguchi, Taketo ^c   Saisho, Hiromitsu ^c   Tagawa, Masatoshi ^a  

^a CHIBA CANCER CENTER   (Japan)

^b FUDAN UNIVERSITY   (China)

^c CHIBA UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

Colon carcinoma; Gene therapy; IFN ; IL 23; Protective immunity

Indexed keywords

CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GM1; GENE PRODUCT; INTERLEUKIN 23; PROTEIN P19; PROTEIN P40; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR IMMUNITY; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE THERAPY; IMMUNOCOMPETENCE; IMMUNOSTIMULATION; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; TIME SERIES ANALYSIS; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CARCINOMA; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; COLONIC NEOPLASMS; GENE EXPRESSION; GENE THERAPY; INTERFERON TYPE II; INTERLEUKIN-23; INTERLEUKIN-23 SUBUNIT P19; INTERLEUKINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0038795484     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11160     Document Type: Article

References (24)

1. Tepper RI, Mulé JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994;5:153-64.
2. Tagawa M. Cytokine therapy for cancer. Curr Pharm Des 2000;6:681-99.
3. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;283:787-93.
4. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-25.
5. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F, To W, Wagner J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002;168:5699-708.
6. Tahara H, Lotz MT. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther 1995;2:96-106.
7. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975;35:2434-9.
8. Ebina T, Murata K. Antitumor effect of PSK at a distant site: tumorspecific immunity and combination with other chemotherapeutic agents. Jpn J Cancer Res 1992;83:775-82.
9. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. BioTechniques 1989;7:980-90.
10. Duke GM, Hoffman MA, Palmenberg AC. Sequence and structural elements that contribute to efficient encephalomyocarditis virus RNA translation. J Virol 1992;66:1602-9.
11. Yoshida Y, Tasaki K, Miyauchi M, Narita M, Takenaga K, Yamamoto H, Yamaguchi T, Saisho H, Sakiyama S, Tagawa M. Impaired tumorigenicity of human pancreatic cancer cells retrovirally transduced with interleukin-12 or interleukin-15 gene. Cancer Gene Ther 2000;7:324-31.
12. Farrell HE, Vally H, Lynch DM, Fleming P, Shellam GR, Scalzo AA, Davis-Poynter NJ. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature 1997;386:510-4.
13. Tsai S-CL, Gansbacher B, Tait L, Miller FR, Heppner GH. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J Natl Cancer Inst 1993;85:546-53.
14. Ling P, Gately MK, Gubler U, Stern AS, Lin P, Hollfelder K, Su C, Pan YE, Hakimi J. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 1995;154:116-27.
15. Gillessen S, Carvajal D, Ling P, Podlaski FJ, Stremlo DL, Familletti PC, Gubler U, Presky DH, Stern AS, Gately MK. Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur J Immunol 1995;25:200-6.
16. Kato K, Shimozato O, Hoshi K, Wakimoto H, Hamada H, Yagita H, Okumura K. Local production of the p40 subunit of interleukin 12 suppresses T-helper 1-mediated immune responses and prevents allogeneic myoblast rejection. Proc Natl Acad Sci USA 1996;93:9085-9.
17. Hölscher C, Atkinson RA, Arendse B, Brown N, Myburgh E, Alber G, Brombacher F. A protective and agonistic function of IL-12p40 in mycobacterial infection. J Immunol 2001;167:6957-66.
18. Tasaki K, Yoshida Y, Miyauchi M, Maeda T, Takenaga K, Kouzu T, Asano T, Ochiai T, Sakiyamna S, Tagawa M. Transduction of murine colon carcinoma cells with interleukin-15 gene induces antitumor effects in immunocompetent and immunocompromised hosts. Cancer Gene Ther 2000;7:255-61.
19. Lehmann J, Bellmann S, Werner C, Schröder R, Schütze N, Alber G. IL-12p40-dependent agonistic effects on the development of protective innate and adaptive immunity against Salmonella enteritidis. J Immunol 2001;167:5304-15.
20. Cooper AM, Kipnis A, Turner J, Magram J, Ferrante J, Orme IM. Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J Immunol 2002;168:1322-7.
21. Bendelac A, Rivera MN, Park S-H, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997;15:535-62.
22. Li Y, Newby SA, Johnston JV, Hellström KE, Chen L. Protective immunity induced by B7/CD28-costimulated γδ T cells to the EL-4 lymphoma in allogenic athymic mice. J Immunol 1995;155:5705-10.
23. Mackey MF, Gunn JR, Maliszewsky C, Kikutani H, Noelle RJ, Barth RJ Jr. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 1998;161:2094-8.
24. Kikuchi T, Moore MA, Crystal RG. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 2000;96:91-9.